Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Rite Aid second quarter revenue decreases to 2.5%

Rite Aid Corporation today reported financial results for its fiscal second quarter ended August 28, 2010.

23 Sep 2010

Global Strategy for Women's and Children's Health draws more than $40 billion in resources

Culminating a global summit on the Millennium Development Goals (MDGs), United Nations Secretary-General Ban Ki-moon and Heads of State and Government, along with the private sector, foundations, international organizations, civil society and research organizations, kicked off a concerted world-wide effort to save the lives of more than 16 million women and children.

23 Sep 2010

Wall Street Journal reports on building epidemiological capacity in developing countries

The Wall Street Journal examines programs funded partly by the U.S. government that are helping "Nigeria, Vietnam and dozens of other countries" to expand "efforts to respond to disease threats, as epidemics add to the burden on their health-care systems and new pathogens spread around the globe."

23 Sep 2010

Researchers develop drug to eliminate disease transmission by cough

What if there was a drug that could completely eliminate airborne disease transmission that occurs when someone coughs. Researchers at the University of Alberta believe they have found a way to achieve this.

23 Sep 2010

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

NanoViricides, Inc., announced today that it had reached an agreement with Seaside 88, LP a Florida limited partnership, for the exercise of Seaside's option to purchase an additional $2.5M of the Company's Series B Convertible Preferred Stock.

23 Sep 2010

BARDA awards Rapid Micro Biosystems $6.7M contract to develop rapid sterility testing platform for vaccines

Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology Division.

23 Sep 2010

FDA approves Gilenya capsules for reducing MS relapses

The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

22 Sep 2010

Biomatrica launches DNAgard Blood and DNAstable Blood sample stabilization products

Biomatrica Inc., the leader in room temperature biological sample stabilization, today announced the release of DNAgard® Blood and DNAstable® Blood.

22 Sep 2010

Nationwide Health Information Network tool to convey public health information

One hundred and sixty-six years after Samuel Morse used dots and dashes to telegraph "What hath God wrought?" opening up a whole new world of communication, Indiana has become the first state in the nation to use a potentially equally revolutionary tool, the Nationwide Health Information Network, to convey public health information to the U.S. Centers for Disease Control and Prevention.

22 Sep 2010

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Apricus Biosciences, backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud's syndrome secondary to scleroderma.

22 Sep 2010

MIDAS researchers continue to model how H1N1 may spread

As the United States prepares for the upcoming flu season, a group of researchers supported by the National Institutes of Health continues to model how H1N1 may spread.

22 Sep 2010

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.

22 Sep 2010

Immunization is critical to reduce child deaths

Immunising children against preventable diseases is critical to achieving United Nations-led goals to reduce child deaths, global health and development chiefs said in New York today.

22 Sep 2010

Insuring your health: Coordinated care system helps physicians meet more patient needs

In her latest Kaiser Health News consumer column, Michelle Andrews writes: "If you get sick at night or the weekend, all too often the local emergency room is the only medical facility with an open door.

22 Sep 2010

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

First Edition: September 21, 2010

In today's headlines, news about major insurers' plans to stop offering child-only health policies in advance of new rules.

21 Sep 2010

Tips to protect physical health

Fifteen years ago, the non-profit Educational Television Network created Healthy Aging Month to focus attention on the positive aspects of getting older and to encourage people to learn how to increase longevity and avoid preventable declines in physical, mental and emotional health. Healthy aging is of particular interest as life expectancy in the United States continues to rise. According to the Centers for Disease Control and Prevention, in 2007 the life expectancy was 75.4 for men and 80.4 for women .

21 Sep 2010

Researchers to develop vaccine for plague

Given the many pressing concerns of the day, fear of plague probably isn't what causes most Americans to lose sleep. But for those whose responsibility it is to combat bioterrorism, plague is among the highest priorities. Those charged with that mission include scientists like medical researcher Steve Smiley, whose lab at the Trudeau Institute is working to develop a vaccine that will protect the public against weaponized forms of plague.

21 Sep 2010

Study reveals molecular steps for pneumonia therapy

A structural molecule and the cellular pump that regulates its levels influence the severity of pneumonia and could provide new ways of treating the lung infection, which is a leading cause of hospitalization and death, according to scientists at the University of Pittsburgh and the University of Iowa. Their findings are available online in Nature Medicine.

21 Sep 2010

ProtAffin presents impressive efficacy data for PA401 in COPD

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. This conference is the largest gathering of scientists and clinicians in the respiratory community in the world. The Oral Presentation will be made in the session "Pre-clinical models of airways disease".

21 Sep 2010